Abstract
Purpose :
This study aimed to characterize the population which initially develop exudative age-related macular degeneration (AMD) at a late stage of life (i.e. over 85 years of age).
Methods :
A retrospective, age-matched case-control study was conducted in patients who developed exudative age-related macular degeneration after 85 years of age. Patients who received initial anti-vascular endothelial growth factor (VEGF) injection between Jan., 2017 and Oct., 2018, and aged more than 85 years at the time of exudative AMD development were subject for analysis. We evaluated initial visual acuity, subfoveal choroial thickness, fellow-eye status and other contributions of the known risk factors for exudative AMD.
Results :
Among the 1632 patients who received anti-VEGF during the study period, 35 patients had developed exudative AMD after 85 years of age (mean age 87.6 years). Eighty-nine percent of the fellow eyes had concurrent non-exudative AMD change. Drusenoid PED were prevalent among the exudative eye.
Conclusions :
Certain portion of the highly-aged population develop exudative changes later than others.Future studies on genetic associations may be warrented in those who develop exudative changes at a rather late stage of life.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.